Donor Cytotoxic T-Lymphocytes in Treating Patients With Relapsed Epstein-Barr Virus-Associated Diseases

Inclusion Criteria

• SCREENING
• Any patient, regardless of age or sex, with one or more of the following EBV-positive or associated disorders, regardless of the histological subtype: * Hodgkin lymphoma * Non-Hodgkin lymphoma * Lymphoproliferative disorder * Nasopharyngeal carcinoma * Leiomyosarcoma * Severe chronic active EBV infection syndrome (SCAEBV), defined as high EBV viral load in plasma or peripheral blood mononuclear cell (PBMC) (> 4000 genomes per ug PBMC deoxyribonucleic acid [DNA]) and/or biopsy tissue positive for EBV
• Karnofsky/Lansky score >= 50%
• Informed consent explained to and signed by patient or parent/guardian able to give informed consent and given a copy
• TREATMENT
• Any patients, regardless of age or sex, with one or more of the following EBV-positive or associated disorders, regardless of the histological subtype: * Hodgkin lymphoma * Non-Hodgkin lymphoma * Lymphoproliferative disorder * Nasopharyngeal carcinoma * Leiomyosarcoma * Severe chronic active EBV infection syndrome (SCAEBV), defined as high EBV viral load in plasma or PBMC (> 4000 genomes per Mg PBMC DNA) and/or biopsy tissue positive EBV
• The disease needs to be in one of the following stages: * At diagnosis or in first relapse AND the patient is unable to receive conventional chemotherapy for his/her condition * In second or subsequent relapse * With residual disease after autologous, syngeneic or allogeneic hematopoietic stem cell transplantation (HSCT)
• Life expectancy >= 6 weeks
• Tumor tissue is positive for EBV
• Karnofsky/Lansky score >= 50%
• Bilirubin < 3 x upper limit of normal (ULN)
• Aspartate aminotransferase (AST) < 5 x ULN
• Hemoglobin (Hgb) > 8.0 g/dL
• Serum creatinine < 3 x ULN
• Pulse oximetry of > 90% on room air
• If post allogeneic HSCT, patient must not have less than 50% donor chimerism in either peripheral blood or bone marrow
• Clinical status at enrollment to allow tapering of steroids to less than 0.5 mg/kg/day prednisone at time of treatment
• Informed consent explained to and signed by patient or parent/guardian able to give informed consent and given a copy
• Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 3 months after the study is concluded; the male partner should use condom

Exclusion Criteria

• SCREENING
• Know human immunodeficiency virus (HIV) positivity
• TREATMENT
• Currently receiving any investigational agents or have received any tumor vaccines within previous 4 weeks
• Active acute grade III-IV graft-versus-host disease
• Severe intercurrent infection
• Received alemtuzumab or other anti-Tcell antibody within 28 days
• HIV seropositivity
• Pregnancy (due to unknown effects of this therapy on a fetus) or lactation
• Tumor in a location where enlargement could cause airway obstruction